Login
$YBGJ
$0.01 +$0.01 (120.41%) Close

Ownership

13F as of Q2 2026 · 170.4M shares outstanding

Who owns YBGJ?

By type of holder
Institutions 0.0% Insiders 0.0% Everyone else 100.0%
Concentration Top 4 holders own 126.5%
Flydragon International Ltd 48.1% · Jun Wang 48.1%
Institutional ownership
0.0%
0.0 pts vs last qtr
Institutional holders
0
0 vs last qtr
Net shares bought
0
by institutions in Q2 2026
New / sold out
0 / 0
positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

No 13F manager has reported this stock in the last 8 quarters.

Biggest buyers in Q2 2026

None.

Biggest sellers in Q2 2026

None.

Who is planning to sell?

No insider has filed a notice of proposed sale (Form 144) for Yubo International Biotech Ltd in the last 12 months.

Is your stake being diluted?

Diluted share count, FY2023–FY2025
+1065.4%
+241.39% a year
Each share's claim on the business
−91.4%
shrank without buying or selling a share
Diluted shares, split-adjusted
11.6M76.3M141.0M2023: 12.0M shares'232024: 119.8M shares'242025: 139.6M shares'25

How patient are the owners?

No 13F manager reports holding YBGJ.

Super Investors

Investment managers reporting YBGJ on Form 13F
No 13F manager reports holding YBGJ yet.

Institutional Funds

Mutual funds and ETFs reporting YBGJ on Form N-PORT; together they hold 0.0% of the company
No fund reports holding YBGJ yet.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G
FI
Flydragon International Ltd
5%+ holder13D · 48.1%
Shares
81.9M
% of company
48.08%
Change vs last qtr
—
Held since
—
JW
Jun Wang
5%+ holder13D · 48.1%
Shares
81.9M
% of company
48.08%
Change vs last qtr
—
Held since
—

2 more holders behind a free account

See every insider and 5%+ holder of Yubo International Biotech Ltd.

Sign up free

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support